iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton’s tyrosine kinase inhibitor (BTKi) treatment, CLL remains largely incurable. Frequent disease relapses occur due to re...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Alexander Englisch, Clara Hayn, Susanne Jung, Jonas S. Heitmann, Christopher Hackenbruch, Yacine Maringer, Annika Nelde, Marcel Wacker, Monika Denk, Lisa Zieschang, Christine Kammer, Peter Martus, Helmut R. Salih, Juliane S. Walz
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-08-01
Rangatū:	Frontiers in Oncology
Ngā marau:	chronic lymphocytic leukemia peptide vaccine BTK-inhibitor minimal residual disease immunotherapy phase I trial
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1441625/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!